North American Palladium (OTCMKTS:PALDF) and Opiant Pharmaceuticals (NASDAQ:OPNT) are both small-cap basic materials companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Analyst Recommendations

This is a summary of current ratings for North American Palladium and Opiant Pharmaceuticals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
North American Palladium 0 0 1 0 3.00
Opiant Pharmaceuticals 0 0 2 0 3.00

Opiant Pharmaceuticals has a consensus target price of $42.00, suggesting a potential upside of 228.13%. Given Opiant Pharmaceuticals’ higher possible upside, analysts plainly believe Opiant Pharmaceuticals is more favorable than North American Palladium.


This table compares North American Palladium and Opiant Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
North American Palladium 33.05% 20.31% 16.36%
Opiant Pharmaceuticals -30.98% -32.67% -22.01%


North American Palladium pays an annual dividend of $0.30 per share and has a dividend yield of 3.0%. Opiant Pharmaceuticals does not pay a dividend.

Volatility & Risk

North American Palladium has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500. Comparatively, Opiant Pharmaceuticals has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500.

Earnings & Valuation

This table compares North American Palladium and Opiant Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
North American Palladium $306.17 million 1.90 $91.96 million N/A N/A
Opiant Pharmaceuticals $13.98 million 3.59 -$21.19 million ($7.10) -1.80

North American Palladium has higher revenue and earnings than Opiant Pharmaceuticals.

Institutional and Insider Ownership

20.1% of Opiant Pharmaceuticals shares are held by institutional investors. 1.0% of North American Palladium shares are held by insiders. Comparatively, 30.9% of Opiant Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


North American Palladium beats Opiant Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About North American Palladium

North American Palladium Ltd. produces precious metals in Canada. It explores for palladium, platinum, gold, nickel, copper, and other metals. It primarily holds interest in the Lac des Iles mine that is located to the northwest of Thunder Bay, Ontario. The company was founded in 1968 and is headquartered in Toronto, Canada.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group.

Receive News & Ratings for North American Palladium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for North American Palladium and related companies with's FREE daily email newsletter.